Welcome to our dedicated page for Replimune Group news (Ticker: REPL), a resource for investors and traders seeking the latest updates and insights on Replimune Group stock.
Replimune Group, Inc. reports clinical, regulatory and financial developments for a clinical-stage biotechnology business developing oncolytic immunotherapies for cancer. The company’s proprietary RPx platform uses an engineered HSV-1 backbone intended to promote tumor cell killing, immunogenic cell death and systemic anti-tumor immune responses.
Recurring Replimune news centers on RP1, or vusolimogene oderparepvec, including data from the IGNYTE clinical trial, combination use with nivolumab in advanced melanoma, Biologics License Application activity and FDA complete response letters. Updates also cover RP2 clinical data in advanced solid tumors, scientific presentations at oncology meetings, quarterly financial results, research and development spending, cash runway commentary and management presentations at healthcare conferences.
Replimune Group, Inc. (NASDAQ: REPL) announced that CEO Philip Astley-Sparke will present at the SVB Leerink 10th Annual Global Healthcare Conference on February 24, 2021, at 8:40 AM ET. The presentation will be available via webcast on Replimune's website, with a replay accessible for 90 days post-conference.
Founded in 2015 and based in Woburn, Massachusetts, Replimune is developing oncolytic immuno-gene therapies using its proprietary Immulytic™ platform, aiming to enhance immune responses to cancer treatments.
Replimune Group (NASDAQ: REPL) reported its fiscal third quarter results for 2020, revealing a net loss of $21.8 million, up from $16.2 million a year prior. The company highlighted its progress in advancing its clinical candidates, particularly RP1, RP2, and RP3, with several studies ongoing and initial data expected throughout 2021. Additionally, Replimune's cash position stands at $493.3 million, extending its runway through the second half of 2024. However, the company noted that COVID-19 has impeded patient enrollment in clinical trials.
Replimune Group Inc. (NASDAQ: REPL) announced significant progress in its oncolytic immuno-gene therapy programs. Key developments include ongoing trials for RP1 in combination with Opdivo for anti-PD1 failed melanoma and NSCLC. RP3 dosing has commenced, and new data is expected in 2021. The company has successfully established a commercial-scale GMP manufacturing facility. Despite delays in patient enrollment due to COVID-19, Replimune maintains a strong cash position of $493 million, expected to fund operations through mid-2024.
Replimune Group, Inc. (NASDAQ: REPL) announced that CEO Philip Astley-Sparke will present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 5:20 PM ET. The event will be held virtually, with a simultaneous webcast available on Replimune’s website. The presentation will focus on their innovative oncolytic immuno-gene therapies developed from the Immulytic™ platform, which aims to enhance cancer treatment by boosting immune responses to tumor antigens. A replay of the conference will be accessible for 30 days afterwards.
Replimune Group, Inc. (NASDAQ: REPL) announced the dosing of the first patient in a Phase 1 clinical trial for RP3, an oncolytic immuno-gene therapy. This trial will evaluate RP3 both alone and in combination with anti-PD-1 therapy in patients with advanced solid tumors. RP3 aims to enhance anti-tumor immune responses using a unique combination of immune-activating proteins. The trial focuses on safety, tolerability, and determining a recommended Phase 2 dose, with initial results expected later in 2021.
Replimune Group Inc. (Nasdaq: REPL) announced its senior management team's participation in investor meetings at the SVB Leerink Oncology 1x1 Day on November 19, 2020. The biotechnology company, based in Woburn, MA, focuses on developing oncolytic immuno-gene therapies from its Immulytic™ platform. This innovative approach aims to enhance cancer treatment by leveraging virus replication and immune response to tumor antigens. Replimune's goal is to advance these therapies through clinical development, working alongside other immuno-oncology treatments.
Replimune Group Inc. (NASDAQ: REPL) announced the availability of its posters for the Society for Immunotherapy of Cancer (SITC) annual meeting, held virtually from November 9-14, 2020. The company will actively participate in a press conference presenting updated results from its Phase 1/2 clinical trial of RP1, an oncolytic HSV combined with nivolumab. Two notable presentations include data from a Phase 1 trial of RP2 and updated results from skin cancer cohorts. Replimune focuses on developing oncolytic immuno-gene therapies to enhance cancer treatment efficacy.
Replimune Group, Inc. (Nasdaq: REPL) announced its fiscal Q2 2020 financial results, highlighting significant developments in its oncolytic immuno-gene therapies. The company raised approximately $287 million through a public offering, strengthening its balance sheet for further clinical trials and commercial infrastructure. Updated data showed promising responses in patients using RP1 and RP2, validating their Immulytic™ platform. A Phase 1 trial for RP3 is set to commence soon, while the cash runway is extended into H2 2024. The net loss for the quarter was $20.1 million.
Replimune Group, Inc. (Nasdaq: REPL) has announced a public offering of 4,687,500 shares at $40.00 per share, raising approximately $250 million before expenses. Additionally, the company will offer pre-funded warrants for 1,562,500 shares at $39.9999 each. The offering is expected to close on October 26, 2020. J.P. Morgan, SVB Leerink, and Barclays act as joint book-running managers. This follows a previously filed shelf registration statement with the SEC. The funds raised aim to support the company’s oncolytic immuno-gene therapy development.
Replimune Group, Inc. (Nasdaq: REPL) announced a proposed public offering of $125 million in common stock, with a potential 30-day option for underwriters to purchase an additional $18.75 million. The offering is to be managed by J.P. Morgan and SVB Leerink, subject to market conditions. Proceeds are intended to support Replimune's development of its oncolytic immuno-gene therapies derived from the Immulytic™ platform. This press release is not an offer to sell securities and will be filed with the SEC.